logo
Science Says Introverts Like Me Should Hate The Gym. Here's How I Learned To Love It Anyway

Science Says Introverts Like Me Should Hate The Gym. Here's How I Learned To Love It Anyway

Yahooa day ago
I'm pretty obsessive about fitness – I write so much about its longevity-boosting, anti-ageing benefits, after all, that I can't help but buy into the hype.
I love running, or at least I'm learning to fall back in love with it.
I've started lifting weights and trying fitness trends like 'Japanese walking' and 'Jeffing', partly because they improve vital metrics like my VO2 max, but mostly because of the mood-boosting benefits.
But I was not always this barbell-lifting, creatine-guzzling person – and a new study from scientists at the University College London may reveal why.
I'm an anxious introvert, and I didn't get into fitness until about 23. So it makes sense that the paper found that, in very simplistic terms, exercise is more appealing to extroverts.
In particular, outgoing people seemed to love high-intensity workouts like weightlifting and spin (both of which I only finally managed to try this year).
More neurotic, private types like myself were likelier to find the whole thing mortifying, the paper said.
I definitely felt that way, too, at the start. Here's how I built activity into my life anyway.
I skipped every PE class throughout secondary school because I found the whole process of exercising so chillingly embarrassing.
The Frontiers paper found that neurotic people who weren't extroverts preferred 'being given space for independence and privacy when engaging in exercise', too.
But, like me, these people saw the most significant stress reduction when they did stick to a programme.
I began running in a low mental health dip, but I took it slow (with a Couch to 5k app) and ran away from people, at off-peak park hours.
I also began doing home workouts, which were easy to achieve in the comfort of my own home. This is a great option for people who fear judgment.
You can also, as the study noted, use your personality traits to your advantage.
For instance, those described as being more 'conscientious' (who are not necessarily extroverts) are more likely to stick to a plan when they know its health benefits.
As someone who falls into that camp, I've found that this tendency is big enough to outweigh my panic.
That's not just because I felt too attached to my new health plan to let crying mid-fitness class and leaving the gym in shame (which has happened twice), stop me forever.
I am simply too convinced by the masses of research outlining exercise's benefits to ignore them – my likely neurotic preoccupation with doing 'the right thing' has proven a cheat code to sticking with at-first embarrassing attempts to lift.
Your traits may require different motives. Perhaps extroverts will be drawn in by adrenaline-packed spin classes, while less outgoing people might enjoy short bursts of activity and a well-rounded mixture of aerobic and strength training, the paper found.
And those who hated being perceived in the gym also didn't respond well to devices tracking things like their heart rate and pace (for what it's worth, I would never have finished my first 5k if I'd started off tracking my pace).
Study author Dr Flaminia Ronca said 'we could potentially use this knowledge to tailor physical activity recommendations to the individual – and hopefully help them to become and remain more active'.
Due to the endless benefits of staying active, that's the most important result, the authors add.
If that means nabbing some resistance bands and doing some strengthening moves in the privacy of your living room, so be it. If you hate long, arduous workouts like lengthy runs, opt for shorter bursts of exercise instead.
The key, this paper shows, is mercy, patience, and self-compassion; and having once been terrified of gyms, I can honestly say I'd never have set foot in my new favourite spot without those.
I Tried 'Jeffing' And My Running Pace Skyrocketed
I Tried Walking Like A Jane Austen Heroine, And My Step Count Has Never Been Higher
I'm A Longevity Professor – These 3 Walking Rules Can Help You Live Longer
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

PICU Mortality Higher for Deprived, Minority Children
PICU Mortality Higher for Deprived, Minority Children

Medscape

timean hour ago

  • Medscape

PICU Mortality Higher for Deprived, Minority Children

Children from deprived and ethnic minority backgrounds are more likely to die following admission to paediatric intensive care units (PICU), according to a UK study. The research analysed 245,099 admissions to PICUs between 2008 and 2021, covering 163,163 children across the UK. Overall, 63·1% of PICU admissions were unplanned. Among children for whom ethnicity data were available, 61.4% of admissions were children of White ethnicity, 9.2% Asian, 4.4% Black, 2.8% multiple ethnicities, and 2.4% were classed as 'other'. The study was conducted by a team from Imperial College London, University College London, and the universities of Leicester, Leeds, and Bristol. Poverty Increases PICU Mortality Odds The research, published in The Lancet Child & Adolescent Health , revealed that children living in areas with higher levels of poverty were more likely to be admitted to PICUs, were more severely ill on arrival, and were less likely to survive than children from the least deprived areas. Overall PICU mortality across planned and unplanned admissions was 3.7%. This ranged from 3.1% for children in the least deprived quintile to 4.2% among children in the most deprived. Children living in the most deprived areas had 13% higher odds of death after PICU admission than those living in the least deprived areas. Mortality Highest Among Asian Children Children of ethnic minority backgrounds were more likely than White children to have longer PICU stays (average 66 versus 52 hours) and unplanned readmission to PICU within 60 days of discharge (9% versus 6.8%). Asian children had the highest crude mortality rate at 5.1%, compared with 3.2% for White children. Children of multiple and 'other' ethnicities also had higher odds of dying, with odds ratios of 1.23 and 1.20 respectively. There was no statistically significant difference in mortality between Black and White children (OR 1.04). The researchers noted that although ethnicity was known to contribute to differences in mortality and other health inequalities in children, their study was the first to report worse intensive care outcomes among children from more deprived backgrounds. They concluded that targeted community and hospital-based interventions are needed to improve PICU outcomes. Early Disparities Highlighted Dr Hannah Mitchell Lead researcher Dr Hannah Mitchell, from the Department of Surgery and Cancer at Imperial College London (ICL), said that the disparities mirror those seen in adults, but emerge much earlier, with 44% of children admitted to PICU under 1 year old and 70% under 5 years old. "This suggests that the effects of deprivation and systemic inequality begin very early in life, long before adult risk factors come into play," she told Medscape News UK . Mitchell said that the research team had secured funding to explore why children from more deprived areas, and those of Asian ethnicity, often arrive in PICU more unwell and may continue to deteriorate after admission. A further study would investigate how this might be prevented, she said. Professor Padmanabhan Ramnarayan Senior author Professor Padmanabhan Ramnarayan, also from ICL, described the findings as "worrying". He warned that PICU use is likely to rise as more children develop complex chronic conditions. Dr Helen Stewart, officer for health improvement at the Royal College of Paediatrics and Child Health, said that the study revealed the "deeply alarming" depth of child poverty in the UK. "As a paediatrician, I am increasingly disturbed by the rising number of children presenting with poverty-related illnesses," she told Medscape News UK . Stewart added that 'poverty is a key determinant of health, shaping children's wellbeing and elevating mortality risk in areas of greatest deprivation'. Experts Call for Urgent Action The study followed recent findings from the National Child Mortality Database (NCMD), which reported that over half (54%) of the 9517 deaths in children aged 0 to 17 in England occurring between 1 April 2019 and 31 March 2022 involved children with life-limiting conditions. Karen Luyt, a professor in neonatal medicine at the University of Bristol, and NCMD programme lead, told Medscape News UK: "A plausible hypothesis would be that underlying life limiting conditions might explain the higher mortality rate of Asian children on UK PICUs." The research was commissioned by the Healthcare Quality Improvement Partnership (HQIP) through its national paediatric intensive care audit network (PICANet).

Summit Partners Announces Growth Investment in Dreampath Diagnostics to Accelerate Digital Transformation in Anatomical Pathology
Summit Partners Announces Growth Investment in Dreampath Diagnostics to Accelerate Digital Transformation in Anatomical Pathology

Yahoo

time2 hours ago

  • Yahoo

Summit Partners Announces Growth Investment in Dreampath Diagnostics to Accelerate Digital Transformation in Anatomical Pathology

LONDON & BOSTON & STRASBOURG, France, July 14, 2025--(BUSINESS WIRE)--Summit Partners today announced a growth investment in Dreampath Diagnostics, a leading healthcare technology company focused on digitizing workflows in anatomical pathology laboratories. The investment will support the company's plans to accelerate global growth, scale operations and expand its commercial reach and product portfolio. Founded in 2012, Dreampath offers a patented suite of traceability solutions and consumables designed to automate and digitally transform the archiving and retrieval of tissue samples in pathology labs. Today, the company manages more than 250 million samples across over 500 labs in nearly 40 countries, serving a broad range of healthcare organizations, from hospitals and research institutions to commercial laboratories and cancer centers. "Pathology labs are a critical part of the global healthcare ecosystem, yet many still rely on manual, error-prone processes for sample archiving and retrieval," said Pablo Jordan, CEO and co-founder of Dreampath Diagnostics. "Our mission is to improve the efficiency and accuracy of these workflows through automation and digital traceability, allowing labs to provide patients with faster and safer diagnostics. We're proud to partner with Summit to help us scale our impact and reach more patients around the world." Dreampath's integrated platform is protected by more than 80 patents worldwide and is designed to automate, simplify and streamline lab workflows to help eliminate the risk of patient sample loss. The company's technology is tailored to specific stages of the pathology process and works with Dreampath's proprietary software and consumables. This closed-loop system helps labs archive and retrieve tissue samples with speed and precision, with a focus on improving sample traceability while reducing manual errors, retrieval times and operational burden. Customers using the system have reported meaningful positive results, noting an 83% reduction in time spent archiving tissue samples. Dreampath has grown profitably and rapidly at a CAGR of more than 50% in recent years, driven by strong demand for its platform across the U.S., EMEA and other global markets. Dreampath's customers include many of the world's foremost cancer centers, as well as some of the largest and most sophisticated commercial laboratories in operation today. "Pathology labs are navigating growing volumes, staffing shortages and increasing demands for precision, all while working with systems that haven't meaningfully evolved in decades," said Thomas Tarnowski, Managing Director at Summit Partners. "Dreampath's platform is designed to address a key bottleneck in the pathology workflow. By enabling fast and traceable access to tissue samples, the company is supporting more consistent lab operations and helping improve the quality of patient care. We believe Dreampath is well-positioned to lead the modernization of pathology infrastructure on a global scale." "We were drawn to Dreampath because of their clear leadership in a fast-growing and increasingly essential segment of lab diagnostics," added Jono Pagden, Principal at Summit Partners. "In our view, the company's first-mover advantage, consistent focus on quality and strong customer adoption have helped Dreampath establish a strong reputation as a trusted provider in digital archiving. We're proud to be their first institutional partner and excited to support the team in scaling their impact globally." Both Thomas Tarnowski and Jono Pagden have joined the Dreampath Board of Directors. Dreampath is headquartered in Strasbourg, France with a U.S. commercial office in New York. Financial terms of the transaction were not disclosed. About Dreampath Diagnostics Dreampath Diagnostics is a global leader of digital sample management systems for anatomical pathology laboratories. The company's patented solutions combine purpose-built scanners, software and consumables to enable automated and error-free archiving and rapid retrieval of tissue samples, helping labs accelerate diagnostics, improve accuracy, and compliance. Dreampath's systems are used in leading labs and institutions across nearly 40 countries. For more information, please visit About Summit Partners Summit Partners is a leading growth-focused investment firm. Summit invests across growth sectors of the economy and, since the firm's founding in 1984, has invested in more than 550 companies in technology, healthcare and other growth industries. These companies have completed more than 175 public equity offerings, and more than 250 have been acquired through strategic mergers and sales. Notable investments in healthcare and life sciences include Advance Medical, CluePoints, Healthline Media, LifeStance Health, VaxCare and Viroclinics. Summit maintains offices in North America and Europe and seeks to invest in category-leading, profitable growth companies worldwide. For more information, please visit or follow on LinkedIn. View source version on Contacts Media Contact:Susan Barrsbarr@

Summit Partners Announces Growth Investment in Dreampath Diagnostics to Accelerate Digital Transformation in Anatomical Pathology
Summit Partners Announces Growth Investment in Dreampath Diagnostics to Accelerate Digital Transformation in Anatomical Pathology

Yahoo

time2 hours ago

  • Yahoo

Summit Partners Announces Growth Investment in Dreampath Diagnostics to Accelerate Digital Transformation in Anatomical Pathology

LONDON & BOSTON & STRASBOURG, France, July 14, 2025--(BUSINESS WIRE)--Summit Partners today announced a growth investment in Dreampath Diagnostics, a leading healthcare technology company focused on digitizing workflows in anatomical pathology laboratories. The investment will support the company's plans to accelerate global growth, scale operations and expand its commercial reach and product portfolio. Founded in 2012, Dreampath offers a patented suite of traceability solutions and consumables designed to automate and digitally transform the archiving and retrieval of tissue samples in pathology labs. Today, the company manages more than 250 million samples across over 500 labs in nearly 40 countries, serving a broad range of healthcare organizations, from hospitals and research institutions to commercial laboratories and cancer centers. "Pathology labs are a critical part of the global healthcare ecosystem, yet many still rely on manual, error-prone processes for sample archiving and retrieval," said Pablo Jordan, CEO and co-founder of Dreampath Diagnostics. "Our mission is to improve the efficiency and accuracy of these workflows through automation and digital traceability, allowing labs to provide patients with faster and safer diagnostics. We're proud to partner with Summit to help us scale our impact and reach more patients around the world." Dreampath's integrated platform is protected by more than 80 patents worldwide and is designed to automate, simplify and streamline lab workflows to help eliminate the risk of patient sample loss. The company's technology is tailored to specific stages of the pathology process and works with Dreampath's proprietary software and consumables. This closed-loop system helps labs archive and retrieve tissue samples with speed and precision, with a focus on improving sample traceability while reducing manual errors, retrieval times and operational burden. Customers using the system have reported meaningful positive results, noting an 83% reduction in time spent archiving tissue samples. Dreampath has grown profitably and rapidly at a CAGR of more than 50% in recent years, driven by strong demand for its platform across the U.S., EMEA and other global markets. Dreampath's customers include many of the world's foremost cancer centers, as well as some of the largest and most sophisticated commercial laboratories in operation today. "Pathology labs are navigating growing volumes, staffing shortages and increasing demands for precision, all while working with systems that haven't meaningfully evolved in decades," said Thomas Tarnowski, Managing Director at Summit Partners. "Dreampath's platform is designed to address a key bottleneck in the pathology workflow. By enabling fast and traceable access to tissue samples, the company is supporting more consistent lab operations and helping improve the quality of patient care. We believe Dreampath is well-positioned to lead the modernization of pathology infrastructure on a global scale." "We were drawn to Dreampath because of their clear leadership in a fast-growing and increasingly essential segment of lab diagnostics," added Jono Pagden, Principal at Summit Partners. "In our view, the company's first-mover advantage, consistent focus on quality and strong customer adoption have helped Dreampath establish a strong reputation as a trusted provider in digital archiving. We're proud to be their first institutional partner and excited to support the team in scaling their impact globally." Both Thomas Tarnowski and Jono Pagden have joined the Dreampath Board of Directors. Dreampath is headquartered in Strasbourg, France with a U.S. commercial office in New York. Financial terms of the transaction were not disclosed. About Dreampath Diagnostics Dreampath Diagnostics is a global leader of digital sample management systems for anatomical pathology laboratories. The company's patented solutions combine purpose-built scanners, software and consumables to enable automated and error-free archiving and rapid retrieval of tissue samples, helping labs accelerate diagnostics, improve accuracy, and compliance. Dreampath's systems are used in leading labs and institutions across nearly 40 countries. For more information, please visit About Summit Partners Summit Partners is a leading growth-focused investment firm. Summit invests across growth sectors of the economy and, since the firm's founding in 1984, has invested in more than 550 companies in technology, healthcare and other growth industries. These companies have completed more than 175 public equity offerings, and more than 250 have been acquired through strategic mergers and sales. Notable investments in healthcare and life sciences include Advance Medical, CluePoints, Healthline Media, LifeStance Health, VaxCare and Viroclinics. Summit maintains offices in North America and Europe and seeks to invest in category-leading, profitable growth companies worldwide. For more information, please visit or follow on LinkedIn. View source version on Contacts Media Contact:Susan Barrsbarr@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store